HIMS vs. NTRA, FMS, OPCH, GH, RDNT, SHC, SGRY, BTSG, PRVA, and WGS
Should you be buying Hims & Hers Health stock or one of its competitors? The main competitors of Hims & Hers Health include Natera (NTRA), Fresenius Medical Care (FMS), Option Care Health (OPCH), Guardant Health (GH), RadNet (RDNT), Sotera Health (SHC), Surgery Partners (SGRY), BrightSpring Health Services (BTSG), Privia Health Group (PRVA), and GeneDx (WGS). These companies are all part of the "healthcare" industry.
Hims & Hers Health vs.
Hims & Hers Health (NYSE:HIMS) and Natera (NASDAQ:NTRA) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, community ranking, analyst recommendations and valuation.
Hims & Hers Health has a net margin of 8.19% compared to Natera's net margin of -14.01%. Hims & Hers Health's return on equity of 10.97% beat Natera's return on equity.
Natera received 447 more outperform votes than Hims & Hers Health when rated by MarketBeat users. Likewise, 68.92% of users gave Natera an outperform vote while only 37.07% of users gave Hims & Hers Health an outperform vote.
Hims & Hers Health has higher earnings, but lower revenue than Natera. Natera is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.
63.5% of Hims & Hers Health shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 17.7% of Hims & Hers Health shares are held by insiders. Comparatively, 7.6% of Natera shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Hims & Hers Health presently has a consensus target price of $37.31, suggesting a potential upside of 7.31%. Natera has a consensus target price of $178.12, suggesting a potential upside of 17.84%. Given Natera's stronger consensus rating and higher possible upside, analysts plainly believe Natera is more favorable than Hims & Hers Health.
In the previous week, Hims & Hers Health had 2 more articles in the media than Natera. MarketBeat recorded 34 mentions for Hims & Hers Health and 32 mentions for Natera. Natera's average media sentiment score of 1.03 beat Hims & Hers Health's score of 0.58 indicating that Natera is being referred to more favorably in the news media.
Hims & Hers Health has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Natera has a beta of 1.8, meaning that its stock price is 80% more volatile than the S&P 500.
Summary
Natera beats Hims & Hers Health on 10 of the 18 factors compared between the two stocks.
Get Hims & Hers Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hims & Hers Health Competitors List
Related Companies and Tools
This page (NYSE:HIMS) was last updated on 3/22/2025 by MarketBeat.com Staff
Free HIMS Stock Alerts